Market closed

Larimar Therapeutics/$LRMR

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Larimar Therapeutics

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Ticker

$LRMR
Trading on

Industry

Biotechnology

Employees

42

LRMR Metrics

BasicAdvanced
$593M
Market cap
-
P/E ratio
-$1.15
EPS
0.76
Beta
-
Dividend rate
$593M
0.76
$13.68
$2.23
739K
13.095
12.509
2.185
2.703
-28.55%
-44.50%
2.99
2.99
-8.893
51.54%
-30.04%

What the Analysts think about LRMR

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Larimar Therapeutics stock.

LRMR Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

LRMR Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LRMR

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Larimar Therapeutics stock?

Larimar Therapeutics (LRMR) has a market cap of $593M as of November 13, 2024.

What is the P/E ratio for Larimar Therapeutics stock?

The price to earnings (P/E) ratio for Larimar Therapeutics (LRMR) stock is 0 as of November 13, 2024.

Does Larimar Therapeutics stock pay dividends?

No, Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders as of November 13, 2024.

When is the next Larimar Therapeutics dividend payment date?

Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders.

What is the beta indicator for Larimar Therapeutics?

Larimar Therapeutics (LRMR) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.